ASP2215, a novel FLT3/AXL inhibitor: Preclinical evaluation in acute myeloid leukemia (AML).
Masamichi Mori
Employment or Leadership Position - Masamichi Mori
Naoki Kaneko
Employment or Leadership Position - Astellas Pharma
Yoko Ueno
Employment or Leadership Position - Astellas Pharma
Ruriko Tanaka
Employment or Leadership Position - Astellas Pharma
Kathy Cho
Employment or Leadership Position - Astellas Research Institute of America
Rika Saito
Employment or Leadership Position - Astellas Pharma
Yutaka Kondoh
Employment or Leadership Position - Astellas Pharma
Itsuro Shimada
Employment or Leadership Position - Astellas Pharma
Sadao Kuromitsu
Employment or Leadership Position - Astellas Pharma